关键词:
脂代谢异常; 结直肠癌; 临床特征
Lipid metabolism abnormalities in patients with colorectal cancer: distribution characteristics and clinical value
Zhong-Hua Si, Hei-Ying Jin
Zhong-Hua Si, Hei-Ying Jin,
National Center for Colorectal Surgery, the Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210001, Jiangsu Province, China
Correspondence to
: Hei-Ying Jin, Associate Professor, National Center for Colorectal Surgery, the Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210001, Jiangsu Province, China.
jinheiying@yahoo.com.cn
Received:
August 24, 2011
Revised:
October 26, 2011
Accepted:
November 6, 2011
Published online:
December 8, 2011
AIM
: To investigate the distribution characteristics and clinical significance of lipid metabolism abnormalities in patients with colorectal cancer.
METHODS
: Total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured in patients with colorectal cancer, and all the data were analyzed.
RESULTS
: Of all the patients, 24 had elevated levels of TC, and 135 had normal TC levels; 21 had elevated levels of TG, and 138 had normal TG levels; 13 had elevated levels of HDL-C, 65 had normal HDL-C levels, and 81 had reduced HDL-C levels; 22 had elevated levels of LDL-C, and 137 normal LDL-C levels. These lipid parameters had no obvious correlation with age or tumor type, but were significantly correlated with gender, tumor location and tumor stage.
CONCLUSION
: Patients with colorectal cancer often develop lipid metabolism abnormalities. Gender, tumor location and stage were closely associated with lipid metabolism in patients with colorectal cancer, while age and tumor type had no significant influence on lipid metabolism in these patients.
Nalini N
, Manju V, Menon VP. Effect of spices on lipid metabolism in 1,2-dimethylhydrazine-induced rat colon carcinogenesis.
J Med Food
. 2006;
9
:237-245.
[
PubMed
]
[
DOI
]
Herbey II
, Ivankova NV, Katkoori VR, Mamaeva OA. Colorectal cancer and hypercholesterolemia: review of current research.
Exp Oncol
. 2005;
27
:166-178.
[
PubMed
]
[
DOI
]
Jacobs EJ
, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort.
J Natl Cancer Inst
. 2006;
98
:69-72.
[
PubMed
]
[
DOI
]
Coogan PF
, Smith J, Rosenberg L. Statin use and risk of colorectal cancer.
J Natl Cancer Inst
. 2007;
99
:32-40.
[
PubMed
]
[
DOI
]
Kusama T
, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Gastroenterology
. 2002;
122
:308-317.
[
PubMed
]
[
DOI
]
Katz MS
, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Int J Radiat Oncol Biol Phys
. 2005;
62
:1363-1370.
[
PubMed
]
[
DOI
]
Dessí S
, Batetta B, Anchisi C, Pani P, Costelli P, Tessitore L, Baccino FM. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130).
Br J Cancer
. 1992;
66
:787-793.
[
PubMed
]
[
DOI
]
Oppenheimer MJ
, Oram JF, Bierman EL. Up-regulation of high density lipoprotein receptor activity by gamma-interferon associated with inhibition of cell proliferation.
J Biol Chem
. 1988;
263
:19318-19323.
[
PubMed
]
[
DOI
]
Casey PJ
, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid.
Proc Natl Acad Sci U S A
. 1989;
86
:8323-8327.
[
PubMed
]
[
DOI
]
Firestone RA
. Lipid-lowering agents may fight cancer by denying it LDL.
Int J Cancer
. 2006;
119
:2497.
[
PubMed
]
[
DOI
]
